Content about Allergan

October 8, 2013

Lupin Pharmaceuticals announced today that it has launched its generic gatifloxacin ophthalmic solution 0.5%. Lupin had earlier received final approval from the Food and Drug Administration to market a generic version of Allergan's Zymaxid ophthalmic solution, 0.5%, which is indicated for the treatment of bacterial conjunctivitis.

BALTIMORE — Lupin Pharmaceuticals announced today that it has launched its generic gatifloxacin ophthalmic solution 0.5%. Lupin had earlier received final approval from the Food and Drug Administration to market a generic version of Allergan's Zymaxid ophthalmic solution, 0.5%, which is indicated for the treatment of bacterial conjunctivitis.

September 16, 2013

The McKesson Patient Relationship Solutions was recognized for its best-in-class adherence solutions by being named a finalist in the 2013 PM360 Trailblazer Awards for the second consecutive year.

SCOTTSDALE, Ariz. — The McKesson Patient Relationship Solutions last week was recognized for its best-in-class adherence solutions by being named a finalist in the 2013 PM360 Trailblazer Awards for the second consecutive year. McKesson was named a finalist for the Best Persistence Campaign for a co-pay card program targeting oncology patients.  

June 25, 2013

Drug makers may be allowed to seek approval for a generic version of an eye drug made by Allergan based on lab tests rather than clinical trials, according to published reports.

NEW YORK — Drug makers may be allowed to seek approval for a generic version of an eye drug made by Allergan based on lab tests rather than clinical trials, according to published reports.

In a draft guidance released Friday, the FDA said that due to the efficacy profile of Allergan's drug for dry eyes Restasis (cyclosporine) ophthalmic emulsion, it wouldn't be effective for companies to conduct clinical trials to determine the efficacy of a generic version.

September 7, 2012

McKesson Patient Relationship Solutions has been named a finalist in both the 2012 Medical Marketing and Media Awards and the PM360 Trailblazer Awards, McKesson announced Friday.

SCOTTSDALE, Ariz. — McKesson Patient Relationship Solutions has been named a finalist in both the 2012 Medical Marketing and Media Awards and the PM360 Trailblazer Awards, McKesson announced Friday.

McKesson was named a finalist by MM&M in the "Best Use of Direct Marketing to Consumers" category for its "Lap-Band Behavioral Call" campaign on behalf of Ogilvy Healthworld and Allergan. The MM&M Awards annually recognize creativity and marketing effectiveness in health care.

June 19, 2012

The U.S. Court of Appeals for the Federal Circuit ruled in favor of Watson Pharmaceuticals during patent litigation concerning the drug maker's abbreviated new drug application for an overactive bladder treatment.

PARSIPPANY, N.J. — The U.S. Court of Appeals for the Federal Circuit ruled in favor of Watson Pharmaceuticals during patent litigation concerning the drug maker's abbreviated new drug application for an overactive bladder treatment.

The appeals court affirmed a U.S. District Court for the District of Delaware's decision — made March 31 — that asserted that patents related to Allergan's Sanctura XR (trospium chloride extended-release capsules) are invalid. Watson's ANDA for a generic version of Sanctura XR is pending with the Food and Drug Administration.

April 4, 2012

A court has ruled that patents covering a drug used for overactive bladder are invalid, a company looking to launch a generic version of the drug said.

PARSIPPANY, N.J. — A court has ruled that patents covering a drug designed to treat an overactive bladder are invalid, a company looking to launch a generic version of the drug said.

Watson Pharmaceuticals said the U.S. District Court for the District of Delaware ruled that five patents covering Allergan's Sanctura XR (trospium chloride) extended-release capsules were invalid. Watson's application with the Food and Drug Administration for a generic version are pending, the company said.

April 3, 2012

Watson is challenging the patent protection on two eye drugs made by Allergan, the generic drug maker said Tuesday.

PARSIPPANY, N.J. — Watson is challenging the patent protection on two eye drugs made by Allergan, the generic drug maker said Tuesday.

Watson announced that it had filed with the Food and Drug Administration for generic versions of Allergan's Lumigan and Latisse (bimatoprost) ophthalmic solution. The products contain the same active ingredient in the 0.01% and 0.03% strengths, respectively, and are used to reduce pressure within the eye in patients with open-angle glaucoma or ocular hypertension.

May 9, 2011

Cypress Pharmaceuticals has launched a generic version of an eye care drug made by Boehringer Ingelheim and marketed by Allergan, the company said.

MADISON, Miss. — Cypress Pharmaceuticals has launched a generic version of an eye care drug made by Boehringer Ingelheim and marketed by Allergan, the company said.

Cypress announced the launch of epinastine hydrochloride ophthalmic solution 0.05%, a generic version of Elestat; BI owns the trademark to Elestat and licenses rights to the drug to Allergan. Elestat is used to relieve itching of the eyes resulting from allergic conjunctivitis.

March 9, 2011

Allergan reappointed David Pyott as president earlier this week, adding to his role as chairman and CEO. Pyott will succeed Michael Ball, who has accepted the position of CEO at Hospira, a specialty pharmaceutical and medication delivery company, Allergan reported.

IRVINE, Calif. — Allergan reappointed David Pyott as president earlier this week, adding to his role as chairman and CEO. Pyott will succeed Michael Ball, who has accepted the position of CEO at Hospira, a specialty pharmaceutical and medication delivery company, Allergan reported.

The changeover takes place March 27.

March 8, 2011

Generic drug maker Hospira has appointed Mike Ball as CEO, effective March 28, the company said. Ball currently is president of Allergan.

LAKE FOREST, Ill. — Generic drug maker Hospira has appointed Mike Ball as CEO, effective March 28, the company said. Ball currently is president of Allergan.

Ball, who also was appointed to the company’s board, will replace Christopher Begley, who will assume the role of executive chairman.

February 8, 2011

Valeant Pharmaceuticals subsidiary Biovail Labs International has licensed Canadian rights to a treatment for acne from Allergan, Valeant said Tuesday.

MISSISSAUGA, Ontario — Valeant Pharmaceuticals subsidiary Biovail Labs International has licensed Canadian rights to a treatment for acne from Allergan, Valeant said Tuesday.

Under the terms of the agreement concerning the drug Aczone (dapsone) gel in the 5% strength, Biovail will pay Allergan about $500,000 Canadian dollars (about $504,693) upfront, as well as payments based on net sales.

February 1, 2011

Thanks to technological innovations within mascara, the category has driven sales of eye makeup, and looking forward, mascara formulas that are infused with eyelash-enhancing treatments and packaging that offers greater customization not only will volumize lashes but also sales at retail.


Thanks to technological innovations within mascara, the category has driven sales of eye makeup, and looking forward, mascara formulas that are infused with eyelash-enhancing treatments and packaging that offers greater customization not only will volumize lashes but also sales at retail.


January 31, 2011

Anticipating regulatory approval, MAP Pharmaceuticals and Allergan will collaborate to promote a drug for treating acute migraine to physicians.

IRVINE, Calif. — Anticipating regulatory approval, MAP Pharmaceuticals and Allergan will collaborate to promote a drug for treating acute migraine to physicians.

The two companies announced the collaboration Monday for Levadex (dihydroergotamine), an inhaled drug. Phase-3 trials for the drug are finished, and MAP plans to submit an approval application for the drug to the Food and Drug Administration in the first half of this year.

November 21, 2010

Drug maker OcuSoft has launched a prescription supplement designed to enhance botulinum toxin injections, the...

RICHMOND, Texas Drug maker OcuSoft has launched a prescription supplement designed to enhance botulinum toxin injections, the company said.

 

OcuSoft announced the availability of Zytaze in several chain drug stores around the country.

 

 

The drug is designed to extend the duration of botulinum toxin treatments, such as Allergan’s Botox (onabotulinumtoxinA), and reports have indicated that it extends them by almost 25%.

 

November 11, 2010

The president and CEO of Agensys, a subsidiary of Japanese drug maker Astellas, will retire,...

TOKYO The president and CEO of Agensys, a subsidiary of Japanese drug maker Astellas, will retire, Astellas said Tuesday.

 

Donald Rice founded Agensys as UroGenesys in Santa Monica, Calif., in 1996 for the development of biotech drugs for treating cancer. Astellas acquired Agensys in December 2007.

 

Former Allergan SVP, head of global drug development and chief medical officer Sef Kurstjens will replace Rice as president and CEO of Agensys.

October 17, 2010

A popular beauty treatment has won approval as a medical treatment as well....

SILVER SPRING, Md. A popular beauty treatment has won approval as a medical treatment as well.

 

The Food and Drug Administration announced Friday the approval of Allergan’s Botox (onabotulinumtoxinA) for preventing headaches in adult patients with chronic migraine.

 

 

September 26, 2010

Greenstone announced the launch of an authorized generic version of the Alzheimer’s disease drug Aricept...

September 6, 2010

Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a...

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a version of a drug used to treat eye diseases, Watson said Tuesday.

August 31, 2010

Allergan's optimized reformulation of Lumigan has received approval from the Food and Drug Administration, the...

IRVINE, Calif. Allergan's optimized reformulation of Lumigan has received approval from the Food and Drug Administration, the drug maker said Wednesday.

Lumigan 0.01% (bimatoprost ophthalmic solution) is a first-line therapy indicated for the reduction of elevated intraocular pressure with open-angle glaucoma or ocular hypertension, Allergan said. Lumigan 0.01% will be available in fourth quarter 2010 as the newest addition to Allergan’s comprehensive glaucoma portfolio.

 

August 1, 2010

The Food and Drug Administration has approved a treatment for muscle spasms and twitches....

GREENSBORO, N.C. The Food and Drug Administration has approved a treatment for muscle spasms and twitches.

 

March 2, 2010

Bristol-Myers Squibb is buying most of the rights to an investigational pain drug for $40...

January 20, 2010

An investigational drug for treating dry eye didn’t work as well as its developers hoped,...

January 7, 2008

Looking to untangle itself from FDA conflicts and a patent dispute with drug maker Allergan,...